Related Experiment Videos
Multifaceted intervention to promote beta-blocker use in heart failure
Nancy M Allen LaPointe1, Elizabeth R DeLong, Anita Chen
1Center for Education and Research on Therapeutics, Duke Clinical Research Institute, Durham, NC 27715, USA. allen003@mc.duke.edu
American Heart Journal
|April 29, 2006
Summary
A multifaceted intervention failed to significantly increase beta-blocker use in heart failure (HF) patients. While trends favored the intervention, further strategies are needed to improve evidence-based treatment for HF.
Area of Science:
- Cardiology
- Health Services Research
- Clinical Practice Improvement
Background:
- Beta-blockers are recommended for left ventricular systolic dysfunction due to survival benefits.
- Despite recommendations, beta-blocker underuse remains a significant issue in heart failure (HF) clinical practice.
Purpose of the Study:
- To evaluate the effectiveness of a multifaceted intervention aimed at increasing beta-blocker utilization in patients with heart failure (HF).
Main Methods:
- A prospective, randomized study involving medical practices with at least 15 HF patients.
- Intervention practices received provider/patient education, performance feedback, and expert consultation.
- The primary outcome measured was the proportion of HF patients self-reporting beta-blocker use post-intervention.
Main Results:
- No significant difference in beta-blocker use was observed between intervention and control groups (OR 1.16, P = .2).
- A statistically significant increase in beta-blocker initiation versus discontinuation was noted in the intervention group (P = .02).
Conclusions:
- The multifaceted intervention did not significantly improve the overall proportion of patients taking beta-blockers.
- Further research is required to develop effective strategies for implementing evidence-based treatments and reducing the global burden of HF.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.